UTMD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
8.5M
-2.2%
8.7M
-3.6%
9.0M
-7.8%
9.8M
-1.4%
10.0M
Cost of Revenue
3.8M
+9.6%
3.4M
-9.0%
3.8M
-10.1%
4.2M
-3.4%
4.4M
Gross Profit
4.8M
-9.9%
5.3M
+0.3%
5.3M
-6.1%
5.6M
+0.2%
5.6M
Operating Expenses
2.1M
-22.4%
2.7M
-3.8%
2.8M
-5.7%
3.0M
+24.8%
2.4M
R&D
154.0K
+0.0%
154.0K
-27.4%
212.0K
+26.9%
167.0K
+23.7%
135.0K
SG&A
2.0M
-23.7%
2.6M
-1.8%
2.6M
-7.6%
2.8M
+24.8%
2.3M
Operating Income
2.6M
+3.3%
2.6M
+5.1%
2.4M
-6.5%
2.6M
-18.3%
3.2M
EBITDA
2.9M
-11.2%
3.2M
+1.6%
3.2M
-5.3%
3.4M
-14.6%
3.9M
Net Income
2.7M
+3.1%
2.6M
+1.5%
2.6M
-2.5%
2.6M
-13.7%
3.0M
EPS (Basic)
$0.84
+2.4%
$0.82
+2.5%
$0.80
-2.4%
$0.82
-12.8%
$0.94
EPS (Diluted)
$0.84
+2.4%
$0.82
+2.5%
$0.80
-2.4%
$0.82
-12.8%
$0.94
Shares (Diluted)
3.2M
-0.0%
3.2M
-0.4%
3.2M
-0.3%
3.2M
-1.2%
3.2M
Utah Medical Products (UTMD) โ€” Financials